Clinical Trials
105 trialsA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
MountainTAP-29
Bristol-Myers Squibb
LUMIRAY
Johnson & Johnson Enterprise Innovation Inc.
OrigAMI-5
Janssen Research & Development, LLC
VIRO-25
Genelux Corporation
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
SUNRAY-01
Eli Lilly and Company
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
MK-3475-01E
Merck Sharp & Dohme LLC
TroFuse-036
Merck Sharp & Dohme LLC
KANDLELIT-007
Merck Sharp & Dohme LLC
DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
eVOLVE-02
AstraZeneca
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Nanjing Leads Biolabs Co.,Ltd
NeoCOAST-2
AstraZeneca
TroFuse-019
Merck Sharp & Dohme LLC
PanTumor-101
GlaxoSmithKline
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca
RELATIVITY1093
Bristol-Myers Squibb
TeLuRide-008
Eikon Therapeutics
KRAScendo 170
Hoffmann-La Roche
SOHO-02
Bayer
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
INTerpath-009
Merck Sharp & Dohme LLC
TROPION-Lung15
AstraZeneca
DESTINY-BTC01
AstraZeneca
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
DG-03
AstraZeneca
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Krascendo 2
Hoffmann-La Roche
EV-309
Astellas Pharma Inc
ALTAIR
AstraZeneca
eVOLVE-Meso
AstraZeneca
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Privo Technologies
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc